Newborn screening for X-linked adrenoleukodystrophy: further evidence high throughput screening is feasible.

Mark McIntosh,'s picture
PubMed URL: 
http://www.ncbi.nlm.nih.gov/pubmed/24268529
Author: 
Raymond GV
Author List: 
Theda C
Gibbons K
Defor TE
Donohue PK
Golden WC
Kline AD
Gulamali-Majid F
Panny SR
Hubbard WC
Jones RO
Liu AK
Moser AB
Raymond GV
Journal: 
Mol Genet Metab
PubMed ID: 
24268529
Pagination: 
55-7
Volume: 
111
Issue: 
1
Abstract: 
X-linked adrenoleukodystrophy (ALD) is characterized by adrenal insufficiency and neurologic involvement with onset at variable ages. Plasma very long chain fatty acids are elevated in ALD; even in asymptomatic patients. We demonstrated previously that liquid chromatography tandem mass spectrometry measuring C26:0 lysophosphatidylcholine reliably identifies affected males. We prospectively applied this method to 4689 newborn blood spot samples; no false positives were observed. We show that high throughput neonatal screening for ALD is methodologically feasible.
Published Date: 
January, 2014

Bradley L. Schlaggar, M.D., Ph.D., Named President and CEO of Kennedy Krieger Institute

We’re thrilled to welcome Bradley L. Schlaggar, M.D., Ph.D., to the Kennedy Krieger family as our next President and CEO.

Learn more.

Appointments & Referrals

FIND A SPECIALIST

Publications

Read inspiring stories, news and updates about the Institute's patient care, research, special education, professional training, and community programs.

 

Resource Finder

 

A free resource that provides access to information and support for individuals and families living with developmental disabilities.